Similarly, SPRC treatment protected diabetic mice from cardiac insulin resistance by activating the AKT/GLUT4 signaling, with no obvious improvement on systemic insulin resistance, which were consistent with the improvement of H2S levels in myocardium but not in plasma. Here, AKT1 is linked to Insulin resistance.